Longeveron

Lomecel-B, a therapy for Alzheimer’s Disease, showed promising results in the Phase IIa CLEAR MIND trial, slowing disease progression and demonstrating safety. It improved daily living activities and reduced brain volume loss, with FDA designations supporting its development. The trial involved 48 patients, highlighting its potential impact on Alzheimer’s treatment.